A SETD2 inhibitor with Fast Track Status for hematological malignancies, a CNS-penetrating, ATP-competitive LRRK2 inhibitor for Parkinson’s disease, and an oral nonsteroidal mineralocorticoid receptor antagonist are some examples of this month's MOTM. In the slide deck, you'll find a small molecule that modulates a protein that has only been targeted with antibodies so far and a drug that takes advantage of the glutamate NMDA receptor hypofunction hypothesis. Check out the ten molecule minireviews in the slide deck, which covers: Where are all of the Molecules of the Month in clinical developm...